ライフサイエンスコーパス: event-free

1 y 60% of admissions were recorded as adverse event free.

2 To investigate adverse event free admissions as a potential, patient-centered i

3 We defined adverse event free admissions as those without record of any of

4 -adjusted hospital-specific rates of adverse event free admissions for colorectal procedures showed 1

5 -adjusted hospital-specific rates of adverse event free admissions were calculated using colorectal p

6 KC1 expression correlated strongly with poor event-free and overall survival (P < 0.0001), independen

7 lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) a

8 The estimated 5-year abandonment-sensitive event-free and overall survival rates for the group were

9 The 5-year event-free and overall survival rates were 83.7% +/- 1.1

10 The estimated 5-year event-free and overall survival rates were 92.0% +/- 3.9

11 The 5-year event-free and overall survival rates were, respectively

12 , 6, and 12 months) and predicted for longer event-free and transformation-free survival.

13 For advanced-stage patients who were event free at 2 years, the 5-year risk of relapse was on

14 elapse was only 7.6%, and for those who were event free at 3 years, it was comparable to that of limi

15 Among those who were event-free at 12 months, rates of MI or stent thrombosis

16 gust 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate

17 and nine had sufficient follow-up data to be event-free at 24 months.

18 Among HBR patients who were event free before DAPT discontinuation at 1 month, favor

19 who developed post-MI HF in comparison with event-free controls (data set 1).

20 The 5-year event-free, disease-free, and overall survival rates are

21 0.1% by FC) were evaluated by HTS and FC for event-free (EFS) and overall survival (OS).

22 CILP (primary end point) and event-free (EFS) and overall survival (OS; secondary end

23 3-year event-free estimates were 71% (95% CI 61-78) and 46% (36

24 rison with 250 patients post-MI who remained event free over a median follow-up of 4.9 years.

25 t also predicted for improved probability of event-free (P = .043; e14a2) and transformation-free sur

26 One hundred and sixty-nine consecutive event-free patients of the randomized EXAMINATION study

27 ldren, the Ross procedure had a 12.7% higher event-free probability (death or any reintervention) at

28 ults, where the bioprosthesis had the lowest event-free probability of 78.8%, followed by comparable

29 an-Meier analyses were performed to evaluate event-free rates for IAS, all-cause shock, and complicat

30 Five-year event-free rates were 41.7% for the composite outcome an

31 paroscopic surgery and male sex predicted an event-free recovery.

32 erapy-led trial (CNS9204) had a shorter mean event free survival (EFS) (2.7 versus 8.6 years; p = 0.0

33 BCB1 positivity also correlated with reduced event free survival in patients with incompletely resect

34 subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high i

35 Event free survival was worse for CD56-negative compared

36 e partitioning with univariate Cox models of event-free survival ("survival tree regression") was per

37 .9% [75.8-93.2]; p=0.0161) and poorer 5-year event-free survival (22.2% [CI 5.6-45.9] vs 62.0% [50.4-

38 %, 44.8%, 19.5%, respectively; P < .001) and event-free survival (40.6%, 36.0%, 18.1%, respectively;

39 had numerically but not statistically higher event-free survival (62% versus 46%, P=0.087; hazard rat

40 tage point (95% CI -2 to 3) change in 5-year event-free survival (89% vs 88%).

41 BI patients achieved significantly prolonged event-free survival (90.1% [95% confidence interval, 88.

42 0.65; P=0.012) and greater discrimination of event-free survival (concordance index, 0.61 versus 0.56

43 One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalizatio

44 nts with concurrent DLBCL and FL had similar event-free survival (EFS) (hazard ratio [HR] = 0.95) and

45 Five-year event-free survival (EFS) +/- SE (0.40 +/- 0.01) and ove

46 We developed a risk score to predict event-free survival (EFS) after allogeneic hematopoietic

47 nt therapy has been associated with improved event-free survival (EFS) and overall survival (OS) in e

48 Event-free survival (EFS) and overall survival (OS) were

49 With a median follow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were

50 s old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were

51 The 4-year event-free survival (EFS) and overall survival (OS) were

52 Event-free survival (EFS) and overall survival (OS) were

53 cology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) whil

54 To quantify the relationships between event-free survival (EFS) and overall survival (OS) with

55 avorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) with

56 urrence of LVSD, trends in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and

57 oxicity and the impacts of cardiotoxicity on event-free survival (EFS) and overall survival (OS).

58 ing neoadjuvant chemotherapy (NAC), and both event-free survival (EFS) and overall survival (OS).

59 Four-year event-free survival (EFS) and overall survival estimates

60 The 5-year event-free survival (EFS) and overall survival estimates

61 en's Oncology Group trial ACNS0121 estimated event-free survival (EFS) and overall survival for child

62 We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clin

63 Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8

64 Purpose To investigate whether event-free survival (EFS) can be maintained among childr

65 months is feasible and favorably influences event-free survival (EFS) compared with historical contr

66 r all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36

67 The primary analysis was event-free survival (EFS) for patients < 36 months of ag

68 The median event-free survival (EFS) for the entire study populatio

69 assessed whether augmenting therapy improved event-free survival (EFS) for these patients.

70 The primary objective of the trial was event-free survival (EFS) from randomization.

71 ad morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0

72 ients with CNS-negative disease had a 5-year event-free survival (EFS) of 53% +/- 5% and a 5-year ove

73 ssigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006)

74 We sought to determine the effect on event-free survival (EFS) of staging variables, extent o

75 The 6-year event-free survival (EFS) rate for all patients enrolled

76 Overall survival (OS) and event-free survival (EFS) rates at 10 years were, respec

77 sus 71%, respectively (P = .007), and 5-year event-free survival (EFS) was 51% versus 58% (P = .026).

78 Five-year event-free survival (EFS) was 75.0% in patients with 1q

79 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%).

80 Median event-free survival (EFS) was 78.1 months (95% confidenc

81 The 3-year overall survival was 94%, and event-free survival (EFS) was 91%.

82 The early (P = .02) primary end point of event-free survival (EFS) was evaluated 6 months after c

83 Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively

84 ic factors, early metabolic change, pCR, and event-free survival (EFS) were examined (log-rank test).

85 No significant differences in OS and event-free survival (EFS) were found when comparing ISM,

86 Event-free survival (EFS), an earlier prostate-specific

87 Overall survival (OS), event-free survival (EFS), and disease-free survival (DF

88 with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end

89 The primary endpoint was event-free survival (EFS), and secondary endpoints were

90 emia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant tr

91 Secondary end points included 5-year event-free survival (EFS), distant disease-free survival

92 Treatment outcomes included event-free survival (EFS), overall survival (OS), and cu

93 loid leukemia (AML) is associated with worse event-free survival (EFS), overall survival (OS), and cu

94 Ph(-) had worse failure-free survival (FFS), event-free survival (EFS), transformation-free survival

95 Primary end points were event-free survival (EFS), treatment discontinuation, no

96 d pretreatment risk factors with HL-specific event-free survival (EFS).

97 ls defined using RNA sequencing with pCR and event-free survival (EFS).

98 CS of more than 2 being associated with poor event-free survival (EFS).

99 The main end point was event-free survival (EFS).

100 The primary end point was event-free survival (EFS).

101 Other outcomes of interest included event-free survival (EFS).

102 The primary outcome was event-free survival (EFS); defined as no clinical or rad

103 Event-free survival (EFS, primary endpoint) and other cl

104 ing the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG

105 vage therapy (37% vs 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .0

106 ses to induction treatment reached excellent event-free survival (EFS; 72% v 65%) and overall surviva

107 (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog

108 dverse overall survival (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low

109 or International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disea

110 for death, 0.78; one-sided P=0.009), as was event-free survival (hazard ratio for event or death, 0.

111 Median hematologic event-free survival (hemEFS) was 11.8 months and median

112 2), translating into a prolonged hematologic event-free survival (hemEFS; median, 46.1 vs 28.1 months

113 MOLLI-ECV >/= the median (28.9%) had shorter event-free survival (log-rank, P=0.028).

114 Mel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall surviva

115 .028), disease-free survival (P = .03), and event-free survival (P < .001).

116 ersmith Infant Neurological Examination) and event-free survival (time to death or the use of permane

117 The primary end point was event-free survival (with an event defined as disease pr

118 The 5-year event-free survival (with standard error) did not differ

119 compared with patients with WBS, with median event-free survival 1.1 (0.3-5.9) versus 4.7 (2.4-13.3)

120 The primary outcome was event-free survival 2 years after HSCT.

121 ge 1 tumors had an excellent outcome (5-year event-free survival [EFS] +/- standard deviation [SD], 9

122 nuation for toxicity, progression, or death (event-free survival [EFS]) were estimated.

123 pse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456)

124 diatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall surviva

125 ed overall survival and subgroup analyses of event-free survival according to disease duration at scr

126 We aimed to assess event-free survival after high-dose chemotherapy with bu

127 s (interquartile range: 7-16 months), median event-free survival after IRE was 8 months (95% confiden

128 Event-free survival after relapse was inferior in patien

129 Five-year event-free survival after SLN alone was 93% with no isol

130 to 7-year period, significant improvement in event-free survival after surgical revascularization for

131 rtension is independently associated with CV event-free survival among individuals undergoing evaluat

132 otherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 m

133 rate, duration of response, and overall and event-free survival analyses were by intention-to-treat.

134 5-year event-free survival and 5-year overall survival were est

135 ed risk stratification trees based on 5 year event-free survival and clinical applicability.

136 The hazard ratio for event-free survival and duration of response (P = .0020

137 The 3-year event-free survival and OS rates were 83.2% (95% CI, 79.

138 Event-free survival and overall survival (OS) hazard rat

139 Risk group predicted event-free survival and overall survival (p<0.0001).

140 standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children

141 ut pulmonary nodules, enabling us to compare event-free survival and overall survival between groups

142 dergo HSCT (45.1% [28.4-60.5], p=0.013), but event-free survival and overall survival did not differ

143 OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple coh

144 (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI)

145 The 5-year event-free survival and overall survival rates for the 5

146 The 5-year event-free survival and overall survival were 91.4% (95%

147 Event-free survival and overall survival were determined

148 follow-up of 6.5 years (IQR 4.9-7.9), 5-year event-free survival and overall survival were: 88.9% (95

149 trolled trials to estimate lifetime gains in event-free survival and overall survival with comprehens

150 hen projected incremental long-term gains in event-free survival and overall survival with comprehens

151 diagnosis <2 years) results in satisfactory event-free survival and overall survival, and to correla

152 s) for the effects of radiotherapy timing on event-free survival and subgroup interactions were combi

153 We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (

154 chemotherapy with or without rituximab, with event-free survival as the primary end point.

155 emission with incomplete recovery), inferior event-free survival as well as overall survival in both

156 ed an overall response, a complete response, event-free survival at 12 months and 24 months from enro

157 Event-free survival at 2 years was 77.0% (95% CI 72.1-82

158 late relapses that occurred after achieving event-free survival at 24 months (EFS24).

159 Event-free survival at 3 years was 93.9% (95% confidence

160 Overall and event-free survival at 3 years were 83.9% and 80.4%, res

161 Starting from randomization, the rate of event-free survival at 4 years was 79% (95% confidence i

162 ints of this study were progression-free and event-free survival at 5 years.

163 ypass graft (CABG), with improved long-term, event-free survival attributable to use of the left inte

164 Event-free survival based on interim PET/CT (RIW) respon

165 There was no significant difference in event-free survival between recipients of transplants fr

166 gnificantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year

167 ents with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-l

168 vorable biology (n = 61) had superior 3-year event-free survival compared with patients with one or m

169 patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated a significant be

170 Event-free survival did not differ between treatment gro

171 alysis, patients with preeclampsia had worse event-free survival during 1-year follow-up (P=0.047).

172 with this regimen are excellent, with 2-year event-free survival estimated at 85% (95% confidence int

173 ach associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065,

174 307 event-free survival events were reported (153 in the MAP

175 and were able to obtain updated results for event-free survival for 2153 patients recruited between

176 educed for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized

177 SPIO enhancement was associated with reduced event-free survival for aneurysm rupture or repair (P=0.

178 The groups differed significantly in event-free survival for incident ESRD and composite outc

179 Those with multiple variants had worse event-free survival from all-cause death, cardiac transp

180 x and phenotype, we retrospectively assessed event-free survival from birth to the first clinical vis

181 d a less severe clinical course with greater event-free survival from major cardiac events (P=0.04) c

182 clophosphamide, vincristine, and prednisone, event-free survival has improved and the risk of POD24 h

183 the segregation by iPET response, where the event-free survival hazard ratio was 3.14 (95% confidenc

184 th rituximab remained associated with longer event-free survival in a multivariate analysis.

185 The primary endpoint was 2 year event-free survival in all registered eligible patients

186 x of these genes is associated with inferior event-free survival in both patient cohorts.

187 We sought to analyze long-term chimerism and event-free survival in children undergoing transplantati

188 We aimed to investigate whether event-free survival in children with hepatoblastoma who

189 ERPRETATION: Busulfan and melphalan improved event-free survival in children with high-risk neuroblas

190 , MK-2206 evinced a numerical improvement in event-free survival in its graduating signatures.

191 that adjuvant radiotherapy does not improve event-free survival in men with localised or locally adv

192 NT5C2 mutations were associated with reduced event-free survival in multivariable analysis (hazard ra

193 of an unfavourable outcome (hazard ratio of event-free survival in patients with a MRD of >=10(-2)vs

194 isolone did not improve symptomatic skeletal event-free survival in patients with castration-resistan

195 chemotherapy (>/=10% viable tumour) improved event-free survival in patients with high-grade osteosar

196 with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblas

197 after therapy with a histologic response and event-free survival in pediatric and young adult patient

198 Event-free survival in this group was significantly lowe

199 Interpretation Our data suggest that event-free survival is improved in patients with sickle

200 The primary outcome measure was event-free survival measured in the intention-to-treat p

201 all survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%).

202 ome in the matched HFpEF cohort, with 1-year event-free survival of 62% (95% CI, 60%-64%) versus 65%

203 This study sought to determine cardiac event-free survival of a consecutive cohort with suspect

204 The median event-free survival of all 45 evaluable treatments was 5

205 The event-free survival of male RBM20-carriers was significa

206 Event-free survival of patients diagnosed between 1990 a

207 en previously related to an increased 5-year event-free survival of pediatric pre-B acute lymphoid le

208 Despite this result, the 3-year event-free survival rate (52.9% [44.6% to 62.8%] for Clo

209 The primary outcome was one-year event-free survival rate for the combined end point of d

210 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

211 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

212 ering an overall survival rate of 95% and an event-free survival rate of 92%), and encouraging outcom

213 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

214 The 5-year estimated abandonment-sensitive event-free survival rates for patients undergoing upfron

215 The 5-year event-free survival rates for patients with stages 0 to

216 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

217 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

218 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

219 P5 expression displayed inferior overall and event-free survival rates.

220 Symptomatic relatives had a shorter event-free survival than asymptomatic DCM relatives (P<0

221 powerful predictor of major adverse cardiac event-free survival than choice of therapy (hazard ratio

222 BG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

223 th blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month

224 We evaluated the risk of relapse at event-free survival time points in cHL and compared the

225 as 16.9 months (95% CI 1.5-32.3), and median event-free survival was 11.0 months (1.5-16.7).

226 40% (6/15 of evaluable patients) and median event-free survival was 17 months.

227 n follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for

228 erall survival was 4.3 years, and the median event-free survival was 2.7 years.

229 r disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall sur

230 Median symptomatic skeletal event-free survival was 22.3 months (95% CI 20.4-24.8) i

231 de, and melphalan group had an event; 3-year event-free survival was 50% (95% CI 45-56) versus 38% (3

232 Event-free survival was 50.6% versus 56.6% at 3 years an

233 edian follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87)

234 In all 122 patients, 5-year event-free survival was 59.1% (95% CI 50.5-69.1), 5-year

235 er a median follow-up of 5 years, the 3-year event-free survival was 62% versus 65% ( P = .83).

236 In patients with T-LL, 3-year event-free survival was 63.3% (95% CI, 54.2% to 71.0%),

237 2-year event-free survival was 64.0% (95% CI 56.0-70.9) in the

238 e incidence of EBRT was 5.9% (SE +/- 3), and event-free survival was 69.2% (SE +/- 27.2).

239 Estimated 2-year event-free survival was 69.7% (95% CI 66.2-73.0).

240 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84).

241 months), the overall survival was 91.4%, and event-free survival was 81.4%.

242 e survival was 92% (95% CI 79-97) and 5-year event-free survival was 88% (72-95).

243 Estimated 4-year event-free survival was 89.7% (95% confidence interval 8

244 4-year event-free survival was 92% (95% CI 79-97) and 5-year ev

245 Event-free survival was also worse in patients condition

246 Event-free survival was defined as avoidance of external

247 Two-year event-free survival was estimated at 49.0% (95% confiden

248 1%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group t

249 s, the meta-analysis showed no evidence that event-free survival was improved with adjuvant radiother

250 After a median follow-up of 30 months, event-free survival was longer in the rituximab group th

251 Event-free survival was lower with increasing age at tra

252 -up of 17.25 months (IQR 0.50-30.40), median event-free survival was not reached (95% CI 7.93-NR).

253 After a median follow-up of 4 years, event-free survival was reduced in genetic versus patien

254 By Kaplan-Meier analysis, event-free survival was significantly worse in patients

255 Cumulative event-free survival was significantly worse in patients

256 Event-free survival was similar among TERT-high, ALT(+),

257 Event-free survival was worse in recipients aged 13 year

258 One-year overall and event-free survival were 63% and 46%, respectively.

259 v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.

260 % v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7%

261 The primary endpoint was 3-year event-free survival, analysed by intention to treat.

262 All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up d

263 ted with the International Prognostic Index, event-free survival, and number of circulating Tregs.

264 ed to investigate time to local progression, event-free survival, and OS.

265 icacy in terms of time to local progression, event-free survival, and overall survival (OS).

266 cluding primary refractoriness and relapse), event-free survival, and overall survival.

267 y secondary endpoints were overall survival, event-free survival, and progression-free survival and s

268 We used a harmonised definition of event-free survival, as the time from randomisation unti

269 Investigators supplied results for event-free survival, both overall and within predefined

270 After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, an

271 The primary endpoint was event-free survival, defined as being alive without graf

272 d points of progression-free survival (PFS), event-free survival, duration of response, and overall s

273 The primary endpoints were event-free survival, overall response, and overall survi

274 Secondary end points were event-free survival, overall survival, and safety.

275 The primary outcomes were event-free survival, overall survival, and the pattern o

276 ed with notable excess mortality and reduced event-free survival, particularly under medical manageme

277 ance therapy after transplantation prolonged event-free survival, progression-free survival, and over

278 er B-cell [GCB]-like DLBCL) were observed in event-free survival, progression-free survival, and over

279 Factors associated with event-free survival, relapse-free survival, and incidenc

280 Four-year event-free survival, relapse-free survival, and overall

281 Overall survival (OS), event-free survival, transplant-related mortality (TRM),

282 he primary endpoint was symptomatic skeletal event-free survival, which was assessed in the intention

283 nduction was associated with increased early event-free survival, with no difference in long-term pat

284 ters differ significantly in terms of 4-year event-free survival, with the lowest methylation cluster

285 he primary outcome was investigator-assessed event-free survival.

286 denocarcinoma rarely relapsed after a 3-year event-free survival.

287 agnosis of which were highly associated with event-free survival.

288 iations with disease progression and reduced event-free survival.

289 (P=0.036) were independently associated with event-free survival.

290 f the bundled-payment program on overall and event-free survival.

291 The main outcome of interest was event-free survival.

292 s, CABG affords better major adverse cardiac event-free survival.

293 ed with increased toxicity without improving event-free survival.

294 vHD; overall survival; and chronic-GvHD-free event-free survival.

295 The primary end point was event-free survival.

296 The main outcome was event-free survival.

297 Major cardiovascular adverse events-free survival was worse in patients with MVO (P=0

298 correlated with immune cell infiltration and event-free-survival (EFS).

299 cal outcomes included overall survival (OS), event-free-survival, nonrelapse mortality (NRM), and gra

300 Primary end points were event-free survivals (EFS).